Sermorelin vs CJC-1295: how long is useful?

The short fragment gave chemists a problem

Sermorelin’s plasma half-life after intravenous administration is about 10-12 minutes. In healthy men, GH nevertheless remained elevated for about 3 hours. The molecule’s disappearance and the gland’s response run on different clocks.

Longer-acting GHRH analogs were developed to extend that brief exposure. With DAC technology, CJC-1295 binds albumin, a blood protein that clears slowly, extending the signal. The review of GHRH analog biology provides the broader setting for these modifications.

The appeal of extra duration is clear enough to me. It solves a pharmacological problem. It leaves the clinical question of how much duration is useful unsettled.

The same receptor does not make the same experiment

Both belong to the GHRH-analog side of the comparison. CJC-1295’s longer action sustains GH and IGF-1 differently from the short native fragment. This source list has no direct sermorelin-versus-CJC-1295 trial that establishes better sleep, body composition, strength or long-term health.

The editorial case for sermorelin’s feedback-preserving action is an argument about physiology. Neither ‘longer’ nor ‘closer to natural’ earns a clinical verdict from me without a comparative benefit-and-harm result. The continuous-infusion study in six children is one reason to resist a simple more-is-better story: GH secretion initially rose and later fell.

That was a pediatric GHRH(1-29) infusion experiment, not a CJC-1295 trial. Its outcome cannot be assigned to CJC-1295. Its complication is enough to make persistence an interesting variable rather than an automatic virtue.

Direct HGH belongs in another column

Sermorelin prompts the pituitary to release its own GH. Direct growth hormone administration supplies GH itself. The GHRH review explains the upstream signal and its feedback regulation; Walker’s editorial explores the proposed advantage of preserving that arrangement.

The verdict is where my confidence runs out. A plausible physiological advantage still needs demonstration in patient-important outcomes. The research notes show where sermorelin’s own human findings end, and the amount ledger records the studies without turning them into instructions.